Pfizer (PFE) Given a $40.00 Price Target by Jefferies Group Analysts
Jefferies Group set a $40.00 target price on Pfizer (NYSE:PFE) in a research report sent to investors on Tuesday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Pfizer’s FY2017 earnings at $2.60 EPS, FY2018 earnings at $2.90 EPS, FY2019 earnings at $3.00 EPS, FY2020 earnings at $3.10 EPS, FY2021 earnings at $3.43 EPS and FY2022 earnings at $3.81 EPS.
Several other research firms also recently issued reports on PFE. Nord/LB restated a neutral rating on shares of Pfizer in a report on Wednesday, December 27th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a buy rating in a report on Wednesday, October 11th. Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the stock a neutral rating in a report on Wednesday, November 1st. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a buy rating in a report on Friday, December 15th. Finally, Vetr downgraded shares of Pfizer from a buy rating to a hold rating and set a $37.98 price objective on the stock. in a report on Monday, January 15th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of Buy and an average price target of $38.94.
Pfizer (PFE) traded down $0.05 during trading hours on Tuesday, hitting $36.94. 29,538,400 shares of the stock traded hands, compared to its average volume of 16,490,000. Pfizer has a one year low of $30.90 and a one year high of $37.37. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $220,190.00, a P/E ratio of 22.66, a price-to-earnings-growth ratio of 2.30 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the previous year, the firm posted $0.61 EPS. The business’s revenue was up .9% compared to the same quarter last year. research analysts forecast that Pfizer will post 2.59 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.68%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 78.53%.
Pfizer announced that its board has authorized a share buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. In the last three months, insiders sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer during the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer during the second quarter worth approximately $103,000. D. Scott Neal Inc. lifted its position in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC acquired a new position in shares of Pfizer during the second quarter worth approximately $120,000. Finally, Americafirst Capital Management LLC acquired a new position in shares of Pfizer during the third quarter worth approximately $127,000. Hedge funds and other institutional investors own 69.75% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.